Nivalis starts dosing patients in second phase 2 trial of N91115 to treat CF

US-based clinical-stage pharmaceutical company Nivalis Therapeutics has dosed the first patient in a second phase 2 clinical trial of N91115 to treat cystic fibrosis (CF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news